Prostate Cancer in the UK: Understanding Your Treatment Options

The Diagnosis Moment

Receiving a prostate cancer diagnosis is one of the most disorienting experiences a man can face. In the UK, around 52,000 men are diagnosed each year, making it the most common cancer in men. Yet despite how common it is, the treatment pathway is anything but straightforward. There are multiple options, each with different trade-offs between longevity, quality of life, and side effects. The challenge is not a lack of options, it is making sense of them without an independent guide.

Active Surveillance vs. Immediate Treatment

Not all prostate cancers require immediate intervention. For low-risk, slow-growing tumours, active surveillance, regular PSA tests, MRI scans, and biopsies, can be the most appropriate strategy. The difficulty is that many men feel uncomfortable 'doing nothing,' and some clinicians default to treatment because it feels decisive. An independent review of your Gleason score, PSA trajectory, and MRI findings can help determine whether surveillance is genuinely safe in your case or whether it represents a missed window for action.

Surgery: Radical Prostatectomy

Robotic-assisted radical prostatectomy has become the standard surgical approach in the UK. Centres like The Royal Marsden, University College London Hospital, and The Christie offer high-volume programmes. The key question is not just whether surgery is appropriate, but who performs it. Surgeon volume matters enormously, outcomes improve significantly when the procedure is performed by a surgeon who does more than 100 per year. Asking for a surgeon's personal complication rate and continence outcomes at 12 months is entirely reasonable.

Radiotherapy and Emerging Treatments

External beam radiotherapy (EBRT) and brachytherapy offer alternatives to surgery with different side-effect profiles. Newer approaches like stereotactic body radiotherapy (SBRT) and proton beam therapy are expanding options further. HIFU (high-intensity focused ultrasound) and focal therapy represent a middle ground, treating the tumour while preserving surrounding tissue. These are available at select centres in the UK and may be worth investigating for intermediate-risk cases.

Getting the Right Team

The quality of your multidisciplinary team (MDT) matters as much as the treatment itself. A strong MDT includes a urological surgeon, clinical oncologist, radiologist, pathologist, and clinical nurse specialist, all reviewing your case together. If your MDT discussion felt rushed or you were not given clear reasoning for their recommendation, requesting a second MDT review at a specialist cancer centre is a legitimate and increasingly common step.

How a Health Intelligence Approach Helps

Prostate cancer decisions are rarely binary. They involve weighing personal priorities, sexual function, urinary continence, long-term survival, against clinical evidence that is often presented in a fragmented way. A health intelligence engagement brings structure to this process: independent evidence review, surgeon and centre vetting, MDT analysis, and a clear decision framework tailored to your specific case. The goal is not to override your clinical team, but to ensure you have the full picture before making an irreversible choice.